R&D Towards better quality of life, GNT Pharma


Global New Drug Development Pipeline

FLUSALAZINE Flusalazine / Drug for inflammatory - respiratory diseases and pain

  • Drag from side to side.

  • A novel anti-inflammatory drug documented to be safe in cultured cells and animals and discovered using a ligand- and structure-based drug design to reduce the gastrointestinal side effects of aspirin and the granulocytopenia side effect of sulfasalazine.
  • Pharmacological action: Anti-inflammatory + tissue-protective actions as a pro-drug of crisdesalazine, optimized for the treatment of systemic inflammatory and respiratory diseases.
  • Efficacy has been verified in animal models of acute, inflammatory, and neuropathic pain.
  • Efficacy has been verified in animal models of painful inflammatory diseases such as gastritis, enteritis, and pancreatitis.
  • Efficacy has been verified in animal models of chronic obstructive pulmonary disease (COPD) and asthma (patent application in December 2021).
  • Chronic Inflammatory Disease
  • Pancreatitis
  • Enteritis
  • Gastritis
  • Gloves and Socks Syndrome
  • Asthma
Comparison of Flusalazine and current drugs for inflammation & pain
  • Drag from side to side.

GNT Pharma Pfizer Merk
Drug Flusalazine Celebrex Vioxx
Pharmacological mechanism and efficacy Anti-inflammation, Analgesic action mPGES-1 inhibition COX-2 inhibition COX-2 inhibition
Tissue protection ROS toxicity inhibition - -
Indications Arthritis Arthritis Arthritis
Pancreatitis - -
COPD, Asthma - -
Development/sales status IND Preparation $2.3 billion (2003)
$3.3 billion (2004)
$2.7 billion (2012)
$2.5 billion (2003)
Adverse effect No cardiovascular adverse effects
No gastrointestinal adverse effects
Cardiovascular adverse effects (2005)
Gastrointestinal adverse effects (2012)
Market withdrawal due to cardiovascular adverse effects (2004)
Remark Safety verification in phase 1 clinical trial of active substances Non-clinical stage of mPGES-1 inhibitor Discovery step of mPGES-1 inhibitor
Related Articles